Evaluating Proactive Outreach for Prior Authorization Recertifications in Medicaid Patients

被引:0
|
作者
Vishwanath, Soumya [1 ]
Tran, Stephanie N. [1 ]
Pomfret, Thomas C. [1 ]
Boss, Kaelyn C. [1 ]
Tesell, Mark [1 ]
Price, Mylissa [1 ]
Alper, Caroline J. [1 ]
Muchnik, Lorean [1 ]
Clements, Karen M. [1 ]
Lenz, Kimberly [2 ]
机构
[1] UMass Chan Med Sch Commonwealth Med, 333 South St, Shrewsbury, MA 01545 USA
[2] MassHealth, Off Clin Affairs, Quincy, MA USA
来源
AMERICAN JOURNAL OF MANAGED CARE | 2021年 / 27卷 / 11期
关键词
D O I
10.37765/ajmc.2021.88783
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
OBJECTIVES: To assess the effectiveness of a proactive provider intervention in prompting prior authorization (PA) submissions or provider response prior to PA expiration for medically complex Medicaid patients. STUDY DESIGN: Pre-post outreach study with data from pharmacy claims and provider outreach. METHODS: The intervention and historical comparison (control) groups included expired PAs from December 2019 to February 2020 and from December 2018 to February 2019, respectively. Provider outreach, including telephonic and fax attempts, was conducted over a 2-week period prior to PA expiration. Outcomes were classified as positive or negative based on provider conversation coupled with the result (eg, PA submission) for the intervention group and based solely on pharmacy claims for the control group. The primary end point was the percentage of positive outcomes between the groups, analyzed via chi(2) test. The time from PA expiration to the new PA submission was evaluated via t test. RESULTS: A total of 342 outreach attempts were conducted for 270 PAs representing 193 unique patients. Outreach was more likely to result in positive outcomes in the intervention group vs no outreach in the control group (87% vs 25%; P < .00001). On average, PAs were submitted 3.5 days prior to expiration in the intervention group vs 13.0 days after expiration in the control group (t = -7.50; P < .00001). CONCLUSIONS: Proactive outreach resulted in a greater percentage of PA submissions and a significantly reduced time to PA submission. These findings provide important information for payers in guiding clinical programs to enhance continuity of care among at-risk populations.
引用
收藏
页码:E395 / E399
页数:5
相关论文
共 50 条
  • [31] Effects of Prior Authorization on Medication Discontinuation Among Medicaid Beneficiaries With Bipolar Disorder
    Zhang, Yuting
    Adams, Alyce S.
    Ross-Degnan, Dennis
    Zhang, Fang
    Soumerai, Stephen B.
    PSYCHIATRIC SERVICES, 2009, 60 (04) : 520 - 527
  • [32] Medicaid prior-authorization programs and the use of cyclooxygenase-2 inhibitors
    Fischer, MA
    Schneeweiss, S
    Avorn, J
    Solomon, DH
    NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (21): : 2187 - 2194
  • [33] Prior Authorization Requirements and Medicaid Enrollees' Use of Tobacco Cessation Medications, Colorado, 2023
    Dillender, Marcus
    Mermelstein, Robin
    AMERICAN JOURNAL OF PUBLIC HEALTH, 2025, 115 (01) : 42 - 46
  • [34] Prior authorization policies for selective cyclooxygenase-2 inhibitors in medicaid - A policy review
    Fischer, Michael A.
    Cheng, Hailu
    Schneeweiss, Sebastian
    Avorn, Jerry
    Solomon, Daniel H.
    MEDICAL CARE, 2006, 44 (07) : 658 - 663
  • [35] Coverage and Prior Authorization Policies for Medications for Opioid Use Disorder in Medicaid Managed Care
    Abraham, Amanda J.
    Andrews, Christina M.
    Harris, Samantha J.
    Westlake, Melissa M.
    Grogan, Colleen M.
    JAMA HEALTH FORUM, 2022, 3 (11): : E224001
  • [36] The Effect of Medicaid Peer Review Prior Authorization Policies on Pediatric Use of Antipsychotic Medications
    Burcu, Mehmet
    Zito, Julie M.
    McKean, Stephen
    Warnock, Rob
    Herbert, Peter
    Verma, Sumit
    Worrall, Chris M.
    Chu, Steve
    Mohamadi, Ali
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2015, 24 : 16 - 17
  • [37] Spillover effects of state medicaid antipsychotic prior authorization policies inUS commercially insuredyouth
    Spence, O'Mareen
    Reeves, Gloria
    DosReis, Susan
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 (09) : 1064 - 1071
  • [38] Cost analysis of a prior authorization program for anti-obesity therapy in a Medicaid population
    Grauer, DW
    Karpinski, TA
    VALUE IN HEALTH, 2004, 7 (03) : 328 - 328
  • [39] Impact of Medicaid prior authorization requirement for COX-2 inhibitor drugs in Nebraska
    Siracuse, Mark V.
    Vuchetich, Phillip J.
    HEALTH SERVICES RESEARCH, 2008, 43 (01) : 435 - 450
  • [40] Prior Authorization in the Treatment of Patients with pDPN and FM
    Placzek, Hilary E. D.
    Masters, Elizabeth T.
    Gu, Tao
    Cappelleri, Joseph C.
    Wasser, Thomas E.
    Clair, Andrew G.
    Cook, Joseph P.
    Eisenberg, Debra F.
    PAIN PRACTICE, 2015, 15 (01) : E9 - E19